WAVE Life Sciences (WVE) had its price target raised by Canaccord Genuity Group Inc. from $43.00 to $52.00. They now have a "buy" rating on the stock.
WAVE Life Sciences (WVE) had its price target raised by Wedbush from $33.00 to $35.00. They now have an "outperform" rating on the stock.
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference [Yahoo! Finance]
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference
WAVE Life Sciences (WVE) had its "buy" rating reaffirmed by HC Wainwright. They now have a $30.00 price target on the stock.